Being the Co-founder of Trinomab, Dr. Liao holds a Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill (UNC-CH).  Known as the formal professor at Duke University School of Medicine and the Duke Human Vaccine Institute, he has over 40 years of pioneering research experience in virology, immunology, vaccine development, and humoral immune response mechanisms. As the globally renowned immunologist and virologist, Dr. Liao has played a key role in the first isolation of the epidemic hemorrhagic fever virus in China. In addition, his outstanding work contributed to the wide areas of HIV infection, HIV vaccine development, research on antibody protection mechanisms, as well as his studies on antibody profiles following influenza virus vaccination and infection worldwide. He has published over more than 200 peer-reviewed research papers at world top-tier academic journals such as Nature, Science and Cell, demonstrating his expertise in cutting-edge monoclonal antibody theories and technologies. 

Currently, he leads the company’s overall effort for the innovative IPs registration, the mAb discovery, and coordinates the entire mAb process development, preclinical and clinical trial development and the final regulatory filings.

Being Co-founder of Trinomab, Mr. Zheng holds an MBA from Peking University HSBC Business School and possesses more than 20 years of profound industry expertise. He brings extensive experience of biopharmaceutical commercialization, corporate operating management and strategic planning. As the former General Manager of Beijing Chia Tai Lvzhou Pharmaceutical Co., Ltd., he has successfully led the end-to-end commercialization of multiple anti-infective drugs, achieved both the acceleration of market penetration and the expansion of the commercial partnership within the drug sale networks in China. 

In 2015, he co-founded Trinomab with Dr. Liao Huaxin, and currently he is overseeing the company's strategic development planning, overall operation management, and investment/financing initiatives. Under his leadership, the company has not only established the differentiated competitive strategies, collaboration paths with the partners for development of many key products, but also accelerated the transformation of innovative drug from the concept to the patient application.